semaglutide or tirzepatide. Tirzepatide vs. for Weight Loss Weight loss: Semaglutide or tirzepatide,

Dapagliflozin monotherapy in drug-nave patients with diabetes: A randomized-controlled trial of low-dose range

Cardiovascular risk prediction in chronic kidney disease

Because GHK-Cu's anti-inflammatory action is selective rather than broadly suppressive, it calms rosacea-prone and reactive skin without the barrier-thinning tradeoffs of steroid-based approaches

Start your intake Sustained Weight Loss Over Years of GLP-1 Treatment Clinical trials tracking patients for 23 years show that weight loss plateaus typically occur within 1218 months, then stabilizes at a reduced level rather than reversing

In a rodent model, a novel GLP-1R/GIPR/GCGR triple agonist, SAR441255, has been shown to promote weight loss and the maintenance of healthy blood glucose levels and is superior to the GLP-1R/GCGR dual agonist (Saxena et al., 2023)